High-Dose Rifampicin Mediated Systemic Alterations of Cytokines, Chemokines, Growth Factors, Microbial Translocation Markers, and Acute-Phase Proteins in Pulmonary Tuberculosis
High-dose rifampicin (HDR) is now undergoing clinical trials to improve the efficacy of anti-tuberculosis treatment (ATT). However, the influence of HDR in the modulation of different cytokines, chemokines/growth factors, microbial translocation markers (MTMs), and acute-phase proteins (APPs) in pul...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.896551/full |
| _version_ | 1818108515974119424 |
|---|---|
| author | Gokul Raj Kathamuthu Perumal Kannabiran Bhavani Manjula Singh Jitendra Kumar Saini Ashutosh Aggarwal Mohammed Soheb S. Ansari Rajiv Garg Subash Babu Subash Babu |
| author_facet | Gokul Raj Kathamuthu Perumal Kannabiran Bhavani Manjula Singh Jitendra Kumar Saini Ashutosh Aggarwal Mohammed Soheb S. Ansari Rajiv Garg Subash Babu Subash Babu |
| author_sort | Gokul Raj Kathamuthu |
| collection | DOAJ |
| description | High-dose rifampicin (HDR) is now undergoing clinical trials to improve the efficacy of anti-tuberculosis treatment (ATT). However, the influence of HDR in the modulation of different cytokines, chemokines/growth factors, microbial translocation markers (MTMs), and acute-phase proteins (APPs) in pulmonary tuberculosis (PTB) is not well known. PTB individuals were separated into three different arms (R10, R25, and R35) based on their rifampicin dosage. We examined the circulating levels of Type 1, Type 2, pro-inflammatory/regulatory cytokines, chemokines/growth factors, MTMs, and APPs at baseline and after completion of the second month of ATT by ELISA. The baseline levels of cytokines, chemokines/growth factors, MTMs, and APPs did not (except IL-5, IL-6, IL-17A, MCP-1, MIP-1β, GCSF, SAA, ⍺2 MG, Hp) significantly differ between the study individuals. However, at the second month, the plasma levels of Type 1 (TNFα and IFNγ), Type 2 (IL-4, IL-5, and IL-13), pro-inflammatory/regulatory cytokines (IL-6, IL-17A, IL-10, and GMCSF), and APPs were significantly decreased in R35 regimen- compared to R25 and/or R10 regimen-treated PTB individuals. In contrast, the plasma levels of IL-2, IL-8, MCP-1, MIP-1β, GSF, and MTMs were significantly increased in the R35 regimen compared to R25 and/or R10 regimen-treated PTB individuals. Overall, our data reveal that HDR could potentially be beneficial for host immunity by altering different immune and inflammatory markers. |
| first_indexed | 2024-12-11T02:16:36Z |
| format | Article |
| id | doaj.art-fa0eff977bb94f738add74ff6d1a9117 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-11T02:16:36Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-fa0eff977bb94f738add74ff6d1a91172022-12-22T01:24:10ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-07-011310.3389/fphar.2022.896551896551High-Dose Rifampicin Mediated Systemic Alterations of Cytokines, Chemokines, Growth Factors, Microbial Translocation Markers, and Acute-Phase Proteins in Pulmonary TuberculosisGokul Raj Kathamuthu0Perumal Kannabiran Bhavani1Manjula Singh2Jitendra Kumar Saini3Ashutosh Aggarwal4Mohammed Soheb S. Ansari5Rajiv Garg6Subash Babu7Subash Babu8National Institutes of Health-NIRT-International Center for Excellence in Research, Chennai, IndiaNational Institute for Research in Tuberculosis (NIRT), Chennai, IndiaDivision of Epidemiology & Communicable Diseases, Indian Council of Medical Research, New Delhi, IndiaNational Institute for Tuberculosis and Respiratory Diseases, New Delhi, IndiaPost Graduate Institute of Medical Education and Research, Chandigarh, IndiaBhagwan Mahavir Medical Hospital & Research Centre, Hyderabad, IndiaKing George’s Medical University, Lucknow, IndiaNational Institutes of Health-NIRT-International Center for Excellence in Research, Chennai, IndiaLaboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United StatesHigh-dose rifampicin (HDR) is now undergoing clinical trials to improve the efficacy of anti-tuberculosis treatment (ATT). However, the influence of HDR in the modulation of different cytokines, chemokines/growth factors, microbial translocation markers (MTMs), and acute-phase proteins (APPs) in pulmonary tuberculosis (PTB) is not well known. PTB individuals were separated into three different arms (R10, R25, and R35) based on their rifampicin dosage. We examined the circulating levels of Type 1, Type 2, pro-inflammatory/regulatory cytokines, chemokines/growth factors, MTMs, and APPs at baseline and after completion of the second month of ATT by ELISA. The baseline levels of cytokines, chemokines/growth factors, MTMs, and APPs did not (except IL-5, IL-6, IL-17A, MCP-1, MIP-1β, GCSF, SAA, ⍺2 MG, Hp) significantly differ between the study individuals. However, at the second month, the plasma levels of Type 1 (TNFα and IFNγ), Type 2 (IL-4, IL-5, and IL-13), pro-inflammatory/regulatory cytokines (IL-6, IL-17A, IL-10, and GMCSF), and APPs were significantly decreased in R35 regimen- compared to R25 and/or R10 regimen-treated PTB individuals. In contrast, the plasma levels of IL-2, IL-8, MCP-1, MIP-1β, GSF, and MTMs were significantly increased in the R35 regimen compared to R25 and/or R10 regimen-treated PTB individuals. Overall, our data reveal that HDR could potentially be beneficial for host immunity by altering different immune and inflammatory markers.https://www.frontiersin.org/articles/10.3389/fphar.2022.896551/fullpulmonary tuberculosishigh-dose rifampicincytokineschemokinesgrowth factorsacute-phase proteins |
| spellingShingle | Gokul Raj Kathamuthu Perumal Kannabiran Bhavani Manjula Singh Jitendra Kumar Saini Ashutosh Aggarwal Mohammed Soheb S. Ansari Rajiv Garg Subash Babu Subash Babu High-Dose Rifampicin Mediated Systemic Alterations of Cytokines, Chemokines, Growth Factors, Microbial Translocation Markers, and Acute-Phase Proteins in Pulmonary Tuberculosis Frontiers in Pharmacology pulmonary tuberculosis high-dose rifampicin cytokines chemokines growth factors acute-phase proteins |
| title | High-Dose Rifampicin Mediated Systemic Alterations of Cytokines, Chemokines, Growth Factors, Microbial Translocation Markers, and Acute-Phase Proteins in Pulmonary Tuberculosis |
| title_full | High-Dose Rifampicin Mediated Systemic Alterations of Cytokines, Chemokines, Growth Factors, Microbial Translocation Markers, and Acute-Phase Proteins in Pulmonary Tuberculosis |
| title_fullStr | High-Dose Rifampicin Mediated Systemic Alterations of Cytokines, Chemokines, Growth Factors, Microbial Translocation Markers, and Acute-Phase Proteins in Pulmonary Tuberculosis |
| title_full_unstemmed | High-Dose Rifampicin Mediated Systemic Alterations of Cytokines, Chemokines, Growth Factors, Microbial Translocation Markers, and Acute-Phase Proteins in Pulmonary Tuberculosis |
| title_short | High-Dose Rifampicin Mediated Systemic Alterations of Cytokines, Chemokines, Growth Factors, Microbial Translocation Markers, and Acute-Phase Proteins in Pulmonary Tuberculosis |
| title_sort | high dose rifampicin mediated systemic alterations of cytokines chemokines growth factors microbial translocation markers and acute phase proteins in pulmonary tuberculosis |
| topic | pulmonary tuberculosis high-dose rifampicin cytokines chemokines growth factors acute-phase proteins |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.896551/full |
| work_keys_str_mv | AT gokulrajkathamuthu highdoserifampicinmediatedsystemicalterationsofcytokineschemokinesgrowthfactorsmicrobialtranslocationmarkersandacutephaseproteinsinpulmonarytuberculosis AT perumalkannabiranbhavani highdoserifampicinmediatedsystemicalterationsofcytokineschemokinesgrowthfactorsmicrobialtranslocationmarkersandacutephaseproteinsinpulmonarytuberculosis AT manjulasingh highdoserifampicinmediatedsystemicalterationsofcytokineschemokinesgrowthfactorsmicrobialtranslocationmarkersandacutephaseproteinsinpulmonarytuberculosis AT jitendrakumarsaini highdoserifampicinmediatedsystemicalterationsofcytokineschemokinesgrowthfactorsmicrobialtranslocationmarkersandacutephaseproteinsinpulmonarytuberculosis AT ashutoshaggarwal highdoserifampicinmediatedsystemicalterationsofcytokineschemokinesgrowthfactorsmicrobialtranslocationmarkersandacutephaseproteinsinpulmonarytuberculosis AT mohammedsohebsansari highdoserifampicinmediatedsystemicalterationsofcytokineschemokinesgrowthfactorsmicrobialtranslocationmarkersandacutephaseproteinsinpulmonarytuberculosis AT rajivgarg highdoserifampicinmediatedsystemicalterationsofcytokineschemokinesgrowthfactorsmicrobialtranslocationmarkersandacutephaseproteinsinpulmonarytuberculosis AT subashbabu highdoserifampicinmediatedsystemicalterationsofcytokineschemokinesgrowthfactorsmicrobialtranslocationmarkersandacutephaseproteinsinpulmonarytuberculosis AT subashbabu highdoserifampicinmediatedsystemicalterationsofcytokineschemokinesgrowthfactorsmicrobialtranslocationmarkersandacutephaseproteinsinpulmonarytuberculosis |